化学
刘易斯肺癌
药理学
细胞毒性
酶抑制剂
肺癌
酶
药代动力学
生物利用度
IC50型
免疫系统
口服
癌症
免疫抑制
体内
药品
口服活性
腺苷
癌细胞
抗体
前药
紫杉醇
结构-活动关系
铅化合物
生物活性
癌症研究
作用机理
广告
腺苷受体
体外
肺
非竞争性抑制
作者
Yu Fu Xu,菀凌 张,Zhining Liu,Gaofei Qian,Wenzhuang Zhang,Xiaolin Li,Qin Huang,Yun Zhang,Tao Zhu,Nan Cheng,Hua Tang,Xijing Chen,Yisheng Lai
标识
DOI:10.1021/acs.jmedchem.5c03851
摘要
Ecto-5-nucleotidase (CD73), a rate-limiting enzyme in the adenosine pathway, plays a crucial role in mediating tumor immunosuppression and has emerged as an attractive target for cancer immunotherapy. A series of aryl alkyl ether-based CD73 inhibitors were designed and synthesized. Compound LB10 stood out as the most promising inhibitor from this series, with IC50 values of 8.1 nM and 2.7 nM in biochemical and cell-based assays, respectively. This compound was confirmed to be a competitive inhibitor by enzyme kinetic and co-crystallization experiments. The compound exhibited no apparent cytotoxicity and a favorable pharmacokinetic profile. In a syngeneic Lewis lung carcinoma mouse model, oral administration of LB10 significantly inhibited tumor growth and synergized with paclitaxel or an anti-PD-1 antibody via immune activation. Collectively, these results establish LB10 as a promising CD73 inhibitor warranting further development.
科研通智能强力驱动
Strongly Powered by AbleSci AI